Articles related to SMALL CELL LUNG CANCER (SCLC)

Explore the complexities of treating small cell lung cancer (SCLC) after platinum-based therapy failure, including insights into immune checkpoint inhibitors, the preference for lurbinectedin, and the potential of liquid biopsies. Join Dr. Misty Shields in understanding the challenges and opportunities in this evolving field.

The landscape of small cell lung cancer treatment is undergoing significant transformation with the advent of immune checkpoint inhibitors. This shift not only provides new therapeutic options but emphasizes the importance of a comprehensive team approach, including early detection strategies, and holds the promise for enhanced patient prognosis.

The addition of the PD-1 inhibitor serplulimab to chemotherapy significantly prolonged survival compared with chemotherapy alone as first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). Interim analysis of the phase 3 ASTRUM-005 study – comparing serplumimab plus chemotherapy to chemotherapy alone in 1st line extensive stage SCLC – showed a median OS of 15.4 months with serplulimab compared with 10.9 months with placebo. Patients who received serplulimab also had significantly longer median progression-free survival (PFS) 5.8 vs. 4.3 months respectively. The study included 585 patients with untreated extensive stage-SCLC, were randomized 2:1 to serplulimab (4.5 mg/kg) or placebo every 3 weeks. All patients received carboplatin and etoposide every 3 weeks for up to four cycles.

An 87-year-old white man presented to a hospital emergency surgical department with two round, grayish-brown nodules on his abdomen. He had no other complaints except feeling tired and dizzy for the last few months. He had a 120 pack-year smoking history but was not taking any medications and had not experienced a cough, chest pain, shortness of breath, or other breathing problems.

Compared to chemotherapy alone, adebrelimab plus chemotherapy nearly doubled 2-year OS and more than tripled 1-year PFS in patients with extensive-stage SCLC, according to results presented earlier this month at the AACR Annual Meeting 2022. The phase 3 CAPSTONE-1 study evaluated adebrelimab in combination with carboplatin plus etoposide, as first-line treatment for ES-SCLC.

A randomized phase II trial has found that consolidation therapy with nivolumab (Opdivo) plus ipilimumab (Yervoy) after chemoradiotherapy did not lead to better survival outcomes for patients with small cell lung cancer (SCLC). The study enrolled 222 patients with stage I-IIIB histologically or cytologically confirmed limited-disease SCLC, and adequate hematologic, renal, lung, and pulmonary function. The combination regimen yielded no improvement in overall survival, and grade 3 adverse events were approximately 2.5 times more common in the dual therapy group.